The drama surrounding the Alzheimer’s drug Aduhelm (aducanumab) from Biogen (NSDQ:BIIB) continues with the Cleveland Clinic and Mount Sinai refusing to use it until more data are available. The company’s stock dropped 6.79% to $328.16. After FDA decided to conditionally approve the drug for Alzheimer’s disease, three members of an FDA advisory committee have resigned, and politicians and…
Universal flu vaccine shows promise in human trial
Vaccinating against the flu is like shooting at a moving target. Influenza strains continuously mutate, and it is difficult for researchers to identify the three or four strains most likely to post the most significant risk in any given season. As a result, developing flu vaccines is something of a guessing game. According to the…